Post-acute management of the acquired long QT syndrome

Postgraduate Medical Journal

Volumn 90, Issue 1064, 2014, Pages 348-358

  Barra, Sérgio ^a   Agarwal, Sharad ^a   Begley, David ^a   Providência, Rui ^b  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL; CARVEDILOL; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNE2; POTASSIUM CHANNEL KCNQ1; QUINIDINE; SODIUM CHANNEL NAV1.5; SOTALOL; VERAPAMIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ACTION POTENTIAL; CARDIOVASCULAR MORTALITY; DRUG INDUCED DISEASE; ELECTROCARDIOGRAPHY; GENETIC POLYMORPHISM; GENETIC SCREENING; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LONG QT SYNDROME; LONG QT SYNDROME 2; LONG QT SYNDROME 3; POLYMORPHIC VENTRICULAR TACHYCARDIA; QT INTERVAL; QT PROLONGATION; REPOLARIZATION; REVIEW; RISK ASSESSMENT; SUDDEN CARDIAC DEATH; TORSADE DES POINTES; FEMALE; GENETICS; HEART PACING; MALE; PROCEDURES;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; CARDIAC PACING, ARTIFICIAL; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; FEMALE; GENETIC TESTING; HUMANS; LONG QT SYNDROME; MALE; RISK ASSESSMENT;

EID: 84901332256     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2013-132398     Document Type: Review

References (66)

1. Baptista R, Silva S, Dias P, et al. In-hospital prescription of QT-prolonging drugs in a cohort of more than 100,000 patients. Int J Cardiol 2011;147:165-6.
2. Allen LaPointe NM, Curtis LH, Chan KA, et al. Frequency of high-risk use of QT prolonging medications. Pharmacoepidemiol Drug Saf Jun 2006;15:361-8.
3. Curtis LH, Østbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med Fev 2003;114:135-41.
4. Pickham D, Helfenbein E, Shinn JA, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study. Crit Care Med 2012;40:394-9.
5. Pasquier M, Pantet O, Hugli O, et al. Prevalence and determinants of QT interval prolongation in medical inpatients. Intern Med J 2012;42:933-40.
6. Tisdale JE, Wroblewski HA, Overholser BR, et al. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US. Drug Saf 2012;35:459-70.
7. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000;47:219-33.
8. Viskin S, Rosovski U, Sands AJ, et al. Inaccurate electrocardiographic interpretation of long QT: The majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005;2:569-74.
9. Morganroth J, Brozovich FV, McDonald JT, et al. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991;67:774-6.
10. Molnar J, Zhang F, Weiss J, et al. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996;27:76-83.
11. Sadanaga T, Sadanaga F, Yao H, et al. An evaluation of ECG leads used to assess QT prolongation. Cardiology 2006;105:149-54.
12. Bazett HC. An analysis of time relations of electrocardiograms. Heart 1920;7:353-67.
13. Fridericia LS. Duration of systole in electrocardiogram. Acta Med Scand 1920;53:469.
14. Sagie A, Larson MG, Goldberg RJ, et al. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992;70:797-801.
15. Hodges M, Salerno Q, Erlien D. Bazett's QT correction reviewed. Evidence that a linear QT correction for heart rate is better. J Am Coll Cardiol 1983;1:694.
16. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Cardiology 2010;121:1047-60.
17. Roden DM. Taking the idio out of idiosyncratic: predicting torsades de pointes. Pacing Clin Electrophysiol 1998;21:1029-34.
18. Roden DM. Repolarization reserve: a moving target. Circulation 2008;118:981-2.
19. Remme CA, Bezzina CR. Genetic modulation of cardiac repolarization reserve. Heart Rhythm 2007;4:608-10.
20. Kannankeril PJ, Roden DM, Norris KJ, et al. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm 2005;2:134-40.
21. Paulussen ADC, Gilissen RAHJ, Armstrong M, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug induced long QT syndrome patients. J Mol Med 2004;82:182-8.
22. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug associated torsades de pointes. Circulation 2002;105:1943-8.
23. Mank-Seymour AR, Richmond JL, Wood LS, et al. Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes. Am Heart J 2006;152:1116-22.
24. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: a report of the American College of Cardiology/ American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006;27:2099-140.
25. Zhang Y, Post WS, Blasco-Colmenares E, et al. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 2011;22:660-70.
26. Mönnig G, Köbe J, Löher A, et al. Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: a long-term follow-up. Europace 2012;14:396-401.
27. Mönnig G, Köbe J, Löher A, et al. Implantable cardioverter-defibrillator therapy in patients with congenital long QT syndrome: a long-term follow-up. Heart Rhythm 2005;2:497-504.
28. Itoh H, Sakaguchi T, Ding WG, et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circulation 2009;2:511-23.
29. Jamshidi Y, Nolte IM, Dalageorgou C, et al. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol 2012;60:841-50.
30. Kaab S, Crawford DC, Sinner MF, et al. A large candidate gene survey identifies the KCNE1D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circulation 2012;5:91-9.
31. Yamaguchi M, Shimizu M, Ino H, et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci 2003;105:671-6.
32. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm 2005;2(Suppl 2):S30-7.
33. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest 2005;115:2025-32.
34. Mahida S, Hogarth AJ, Cowan C, et al. Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives. J Interv Card Electrophysiol 2013;37:9-19.
35. Hulot JS, Démolis JL, Rivière R, et al. Influence of endogenous oestrogens on QT interval duration. Eur Heart J 2003;24:1663-7.
36. Benoit SR, Mendelsohn AB, Nourjah P, et al. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005;12:363-8.
37. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med 2006;259:59-69.
38. Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270:2590-7.
39. Kannankeril PJ, Norris KJ, Carter S, et al. Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers. Heart Rhythm 2011;8:1530-4.
40. Darbar D, Kimbrough J, Jawaid A, et al. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. J Am Coll Cardiol 2008;51:836-42.
41. Yamaguchi Y, Mizumaki K, Nishida K, et al. Attenuated bradycardia-dependent QT prolongation during atrial fibrillation in patients with paroxysmal atrial fibrillation. Heart Rhythm 2011;8:S416.
42. Milberg P, Ramtin S, Monnig G, et al. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. J Cardiovasc Pharmacol 2004;44:278-86.
43. Frommeyer G, Milberg P, Witte P, et al. A new mechanism preventing proarrhythmia in chronic heart failure: Rapid phase-III repolarization explains the low proarrhythmic potential of amiodarone in contrast to sotalol in a model of pacing-induced heart failure. Eur J Heart Fail 2011;13:1060-9.
44. Topilski I, Rogowski O, Rosso R, et al. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol 2007;49:320-8.
45. Thomsen MB, Oros A, Schoenmakers M, et al. Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation. Cardiovasc Res 2007;73:521-30.
46. Haraoka K, Morita H, Saito Y, et al. Fragmented QRS is associated with torsades de pointes in patients with acquired long QT syndrome. Heart Rhythm 2010;7:1808-14.
47. Kirchhof P, Franz MR, Bardai A, et al. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol 2009;54:143-9.
48. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsades de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
49. Pinski SL, Equia LE, Trohman RG. What is the minimal pacing rate that prevents Torsade de Pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 2002;25:1612-15.
50. Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them? Data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation 2010;122:1272-82.
51. Pinski SL, Eguia LE, Trohman RG. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 2002;25:1612-15.
52. Tan HL, Bardai A, Shimizu W, et al. Genotype-specific onset of arrhythmias in congenital long-QT syndrome: possible therapy implications. Circulation 2006;114:2096-103.
53. Shimizu W, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long QT syndrome. Circulation 1998;98:2314-22.
54. Goldenberg I, Moss AJ. Long QT syndrome. J Am Coll Cardiol 2008;51:2291-300.
55. Viskin S. Cardiac pacing in the long QT syndrome: review of available literature and practical recommendations. J Cardiovasc Electrophysiol 2000;11:593-600.
56. Priori SG, Napolitano C, Schwartz PJ, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA 2004;292:1341-4.
57. Hnatkova K, Gang Y, Batchvarov VN, et al. Precision of QT interval measurement by advanced electrocardiographic equipment. Pacing Clin Electrophysiol 2006;29:1277-84.
58. Letsas KP, Efremidis M, Sideris A. Sotalol unmasks susceptibility to drug-induced long QT syndrome and torsades de pointes. Int J Cardiol 2008;124:366-7.
59. Kaab S, Hinterseer M, Nabauer M, et al. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilot study using i.v. sotalol. Eur Heart J 2003;24:649-57.
60. Towart R, Linders JT, Hermans AN, et al. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening? J Pharmacol Toxicol Methods 2009;60:1-10.
61. Veerman CC, Verkerk AO, Blom MT, et al. Slow delayed rectifier potassium current blockade contributes importantly to drug-induced long QT syndrome. Circ Arrhythm Electrophysiol 2013;6:1002-9.
62. Maruyama M, Xiao J, Zhou Q, et al. Carvedilol analogue inhibits triggered activities evoked by both early and delayed afterdepolarizations. Heart Rhythm 2013;10:101-7.
63. Diness TG, Yeh YH, Qi XY, et al. Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. Cardiovasc Res 2008;79:61-9.
64. Zhou J, Augelli-Szafran CE, Bradley JA, et al. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 2005;68:876-84.
65. Aiba T, Shimizu W, Inagaki M, et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 2005;45:300-7.
66. Miller M, Bhasin K, Weiser T, et al. First report of left cardiac sympathetic denervation for the treatment of drug-induced long QT syndrome. Heart Rhythm 2011;8(5 Suppl. 1):S144.